CA3091307A1 - Csf1r binding agents - Google Patents
Csf1r binding agents Download PDFInfo
- Publication number
- CA3091307A1 CA3091307A1 CA3091307A CA3091307A CA3091307A1 CA 3091307 A1 CA3091307 A1 CA 3091307A1 CA 3091307 A CA3091307 A CA 3091307A CA 3091307 A CA3091307 A CA 3091307A CA 3091307 A1 CA3091307 A1 CA 3091307A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence comprises
- region amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1803226.8A GB201803226D0 (en) | 2018-02-28 | 2018-02-28 | CSF1R Binding agents |
| GB1803226.8 | 2018-02-28 | ||
| GBGB1810226.9A GB201810226D0 (en) | 2018-02-28 | 2018-06-21 | CSF1R binding agents |
| GB1810226.9 | 2018-06-21 | ||
| GB1819045.4 | 2018-11-22 | ||
| GBGB1819045.4A GB201819045D0 (en) | 2018-02-28 | 2018-11-22 | Csf1r binding agents |
| PCT/EP2019/055077 WO2019166596A1 (en) | 2018-02-28 | 2019-02-28 | Csf1r binding agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3091307A1 true CA3091307A1 (en) | 2019-09-06 |
Family
ID=61903334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3091307A Pending CA3091307A1 (en) | 2018-02-28 | 2019-02-28 | Csf1r binding agents |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11655300B2 (enExample) |
| EP (1) | EP3759137A1 (enExample) |
| JP (1) | JP2021514654A (enExample) |
| CN (1) | CN111788229A (enExample) |
| AU (1) | AU2019228110A1 (enExample) |
| CA (1) | CA3091307A1 (enExample) |
| GB (3) | GB201803226D0 (enExample) |
| IL (1) | IL276914A (enExample) |
| SG (1) | SG11202007837RA (enExample) |
| WO (1) | WO2019166596A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240002509A1 (en) * | 2020-11-06 | 2024-01-04 | Novartis Ag | ANTIBODY Fc VARIANTS |
| CN112472790B (zh) * | 2020-12-25 | 2022-12-20 | 同济大学 | 小白蛋白的抑制剂在制备预防治疗肥胖以及肥胖导致的疾病产品中的用途 |
| CN119019548B (zh) * | 2022-07-05 | 2025-06-24 | 东莞市朋志生物科技有限公司 | 抗甲型流感病毒抗体、检测甲型流感病毒的试剂和试剂盒 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0909044B8 (pt) | 2008-03-14 | 2021-05-25 | Transgene Sa | anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos |
| AR080698A1 (es) * | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| KR20140127855A (ko) * | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| GB201315487D0 (en) * | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
-
2018
- 2018-02-28 GB GBGB1803226.8A patent/GB201803226D0/en not_active Ceased
- 2018-06-21 GB GBGB1810226.9A patent/GB201810226D0/en not_active Ceased
- 2018-11-22 GB GBGB1819045.4A patent/GB201819045D0/en not_active Ceased
-
2019
- 2019-02-28 AU AU2019228110A patent/AU2019228110A1/en not_active Withdrawn
- 2019-02-28 SG SG11202007837RA patent/SG11202007837RA/en unknown
- 2019-02-28 EP EP19709003.8A patent/EP3759137A1/en not_active Withdrawn
- 2019-02-28 WO PCT/EP2019/055077 patent/WO2019166596A1/en not_active Ceased
- 2019-02-28 JP JP2020545669A patent/JP2021514654A/ja active Pending
- 2019-02-28 CN CN201980015847.8A patent/CN111788229A/zh active Pending
- 2019-02-28 US US16/976,196 patent/US11655300B2/en active Active
- 2019-02-28 CA CA3091307A patent/CA3091307A1/en active Pending
-
2020
- 2020-08-25 IL IL276914A patent/IL276914A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021514654A (ja) | 2021-06-17 |
| GB201803226D0 (en) | 2018-04-11 |
| US11655300B2 (en) | 2023-05-23 |
| SG11202007837RA (en) | 2020-09-29 |
| GB201819045D0 (en) | 2019-01-09 |
| WO2019166596A1 (en) | 2019-09-06 |
| US20210301026A1 (en) | 2021-09-30 |
| CN111788229A (zh) | 2020-10-16 |
| GB201810226D0 (en) | 2018-08-08 |
| EP3759137A1 (en) | 2021-01-06 |
| IL276914A (en) | 2020-10-29 |
| AU2019228110A1 (en) | 2020-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12173067B2 (en) | C-KIT antibodies and method for treating cancer with such | |
| US12421310B2 (en) | CD47 binding agents | |
| US10858435B2 (en) | PD1 binding agents | |
| US11851460B2 (en) | PD1 binding agents | |
| US12415861B2 (en) | Anti C-MET antibodies | |
| JP7689116B2 (ja) | Ｐｄ１およびｖｅｇｆｒ２二重結合剤 | |
| US10975165B2 (en) | De-immunised anti-ERBB3 antibodies | |
| US11655300B2 (en) | Colony stimulating factor 1 receptor (CSF1R) antibodies and immunoconjugates thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250904 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251104 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251231 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260413 |